{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4"},{"groupId":"OG001","value":"0.36"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"213"},{"groupId":"OG001","value":"209"}],"units":"Participants"}],"description":"Objective response is defined as confirmed complete and partial responses using Response Evaluation Criteria in Solid Tumors criteria. A complete response (CR) is defined as a disappearance of all target lesions. A partial response (PR) is defined as having at least a 30% decrease in the sum of the longest diameter of target lesions taking as reference the baseline sum.\n\nIn each arm, the number of patients reporting a CR or PR was divided by the number of patients evaluable in each arm to obtain the proportion.","groups":[{"description":"Patients receive gemcitabine hydrochloride and cisplatin as in arm I. Patients also receive bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive bevacizumab IV over 30-90 minutes every 21 days in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Arm II (GCB)"},{"description":"Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and cisplatin IV and placebo IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive placebo IV over 30-90 minutes every 21 days in the absence of disease progression or unacceptable toxicity.","id":"OG001","title":"Arm I (GCP)"}],"paramType":"NUMBER","populationDescription":"All patients registered, eligible and assessed for a response are included in this analysis.","reportingStatus":"POSTED","timeFrame":"Up to 7 years","title":"Objective Response","type":"SECONDARY","unitOfMeasure":"proportion of participants"}